These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 35073169)

  • 1. Pathogenesis of Triple-Negative Breast Cancer.
    Derakhshan F; Reis-Filho JS
    Annu Rev Pathol; 2022 Jan; 17():181-204. PubMed ID: 35073169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancer.
    Judes G; Rifaï K; Daures M; Dubois L; Bignon YJ; Penault-Llorca F; Bernard-Gallon D
    Cancer Lett; 2016 Nov; 382(1):77-85. PubMed ID: 26965997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.
    Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M
    BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
    Mehlich D; Marusiak AA
    Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
    Yam C; Mani SA; Moulder SL
    Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple-Negative Breast Cancer: Next-Generation Sequencing for Target Identification.
    Marotti JD; de Abreu FB; Wells WA; Tsongalis GJ
    Am J Pathol; 2017 Oct; 187(10):2133-2138. PubMed ID: 28734944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple-negative breast cancer and basal-like subtype : Pathology and targeted therapy.
    Bando Y; Kobayashi T; Miyakami Y; Sumida S; Kakimoto T; Saijo Y; Uehara H
    J Med Invest; 2021; 68(3.4):213-219. PubMed ID: 34759133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of triple-negative breast cancer.
    Kumar P; Aggarwal R
    Arch Gynecol Obstet; 2016 Feb; 293(2):247-69. PubMed ID: 26341644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
    Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
    Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of triple negative breast cancer for surgical oncologists.
    Sharma S; Barry M; Gallagher DJ; Kell M; Sacchini V
    Surg Oncol; 2015 Sep; 24(3):276-83. PubMed ID: 26092709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
    Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
    Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancer.
    Cheng T; Wu Y; Liu Z; Yu Y; Sun S; Guo M; Sun B; Huang C
    Front Immunol; 2022; 13():970950. PubMed ID: 36052076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular subtypes of triple-negative breast cancer: understanding of subtype categories and clinical implication.
    Lee YM; Oh MH; Go JH; Han K; Choi SY
    Genes Genomics; 2020 Dec; 42(12):1381-1387. PubMed ID: 33145728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances of transcriptomics and proteomics in triple-negative breast cancer prognosis assessment.
    Li Y; Kong X; Wang Z; Xuan L
    J Cell Mol Med; 2022 Mar; 26(5):1351-1362. PubMed ID: 35150062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on triple-negative breast cancers - highlighting subtyping update and treatment implication.
    Tsang JY; Tse GM
    Histopathology; 2023 Jan; 82(1):17-35. PubMed ID: 36468263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple-negative breast cancer molecular subtyping and treatment progress.
    Yin L; Duan JJ; Bian XW; Yu SC
    Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of an immune-suppressed subtype of feline triple-negative basal-like invasive mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Simbault L; Abadie J; Loussouarn D; Campone M; Nguyen F
    Tumour Biol; 2020 Jan; 42(1):1010428319901052. PubMed ID: 31959092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease.
    Qattan A
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple negative breast cancer: looking for the missing link between biology and treatments.
    Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
    Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.